Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia
References (22)
- et al.
Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia
Lancet
(1991) - et al.
Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukaemia and allied diseases
Blood
(1953) - et al.
Are children with lymphoblastic leukaemia given enough 6-mercaptopurine?
Lancet
(1987) - et al.
Genetic variation in response to 6-mercaptopurine for childhood lymphoblastic leukaemia
Lancet
(1990) - et al.
High performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample
J Chromatogr
(1992) Intravenous mercaptopurine-life begins at 40
J Clin Oncol
(1993)- et al.
Variable 6-mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia
J Clin Oncol
(1989) - et al.
Results of Medical Research Council Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Childhood Leukaemia)
Br J Haematol
(1991) - et al.
The UK protocol for childhood ALL 1985-1990
Leukaemia
(1992) - et al.
Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia
Am J Pediatr Hematol Oncol
(1993)
There are more references available in the full text version of this article.
Cited by (206)
Design, synthesis of novel substituted imidazole derivatives: Cytotoxicity and molecular docking studies
2023, Chemical Data CollectionsEmploying metal-doped carbon nanocones for the drug delivery of purinethol anticancer: Insights from DFT calculations
2023, Diamond and Related MaterialsImpact of Mercaptopurine Metabolites on Disease Outcome in the AIEOP-BFM ALL 2009 Protocol for Acute Lymphoblastic Leukemia
2023, Clinical Pharmacology and Therapeutics
Copyright © 1994 Published by Elsevier Ltd.